Investigation of the relationship between matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase with SARS CoV-2 infections

SARS-CoV-2 stands for severe acute respiratory syndrome coronavirus 2 which is the causative agent of spreading coronavirus disease 2019 that is known as COVID-19 pandemic, the disease leads to severe acute respiratory illness. Matrix metalloproteinases- 9 (MMP-9) plays several important physiological functions. This enzyme could also be implicated in the "cytokine storm" in some way, which may represent one of the possible scianrios during coronavirus infection, in addition to its role in the mechanism of lung fibrosis on molecular basis.. The tissue inhibitors of metalloproteinase (TIMPs) are well characterized for controlling the activity of MMPs in extracellular matrix remodeling. They also considered as signaling molecules analogous to cytokine activities in the sense of impact on a variety of biological processes; this study aimed to investigate the link between each of matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of metalloproteinase-1 (TIMP-1), and COVID19 disease. A total of 58 COVID-19 patients and 30 apparently healthy adults were enrolled in this study. The ORF1ab, E. and N genes of SARS-CoV-2 were detected using Multiplex real-time PCR, while the ELISA technique was used to estimate the level of serum matrix metalloproteinase-9 (MMP-9), tissue inhibitor of metalloproteinase-1 (TIMP-1), and CRP. The study results demonstrated higher concentrations of matrix metalloproteinase-9 (MMP-9) in COVID-19 patients compared with controls, with non-significant differences obtained. Unlike, tissue inhibitor of metalloproteinase-1 (TIMP-1), showed considerably higher levels in the patients group than in controls, with high significant differences according to the data statistical analysis (p≤0.001). In a conclusion, the rising trend of TIMP-1 in COVID patients could be promising to suggest serum tissue inhibitor of metalloproteinase-1 (TIMP-1) as an applicable biomarker in the diagnosis of COVID‐19. [ J Adv Biotechnol Exp Ther 2023; 6(1.000): 35-43